Natriuretic peptide receptor-3 underpins the disparate regulation of endothelial and vascular smooth muscle cell proliferation by C-type natriuretic peptide.
Natriuretic peptide receptor-3 underpins the disparate regulation of endothelial and vascular smooth muscle cell proliferation by C-type natriuretic peptide.
复制标题
DOI:
10.1111/j.1476-5381.2011.01400.x
复制
发表时间:
2011-09
影响因子:
7.3
通讯作者:
Hobbs AJ
中科院分区:
文献类型:
--
作者:
Khambata RS;Panayiotou CM;Hobbs AJ
C-type natriuretic peptide (CNP) is an endothelium-derived vasorelaxant, exerting anti-atherogenic actions in the vasculature and salvaging the myocardium from ischaemic injury. The cytoprotective effects of CNP are mediated in part via the Gi-coupled natriuretic peptide receptor (NPR)3. As GPCRs are well-known to control cell proliferation, we investigated if NPR3 activation underlies effects of CNP on endothelial and vascular smooth muscle cell mitogenesis. Proliferation of human umbilical vein endothelial cells (HUVEC), rat aortic smooth muscle cells (RAoSMC) and endothelial and vascular smooth muscle cells from NPR3 knockout (KO) mice was investigated in vitro. CNP (1 pM–1 µM) facilitated HUVEC proliferation and inhibited RAoSMC growth concentration-dependently. The pro- and anti-mitogenic effects of CNP were blocked by the NPR3 antagonist M372049 (10 µM) and the extracellular signal-regulated kinase (ERK) 1/2 inhibitor PD98059 (30 µM) and were absent in cells from NPR3 KO mice. Activation of ERK 1/2 by CNP was inhibited by Pertussis toxin (100 ng·mL−1) and M372049 (10 µM). In HUVEC, ERK 1/2 activation enhanced expression of the cell cycle promoter, cyclin D1, whereas in RAoSMC, ERK 1/2 activation increased expression of the cell cycle inhibitors p21waf1/cip1 and p27kip1. A facet of the vasoprotective profile of CNP is mediated via NPR3-dependent ERK 1/2 phosphorylation, resulting in augmented endothelial cell proliferation and inhibition of vascular smooth muscle growth. This pathway may offer an innovative approach to reversing the endothelial damage and vascular smooth muscle hyperplasia that characterize many vascular disorders.
登录
查看更多内容
DOI:
10.1016/0006-291x(91)90627-j
发表时间:
1991-06-28
影响因子:
3.1
作者:
FURUYA, M;YOSHIDA, M;MATSUO, H
通讯作者:
MATSUO, H
DOI:
10.1016/0735-1097(96)00206-9
发表时间:
1996-09-01
影响因子:
24
作者:
FitzGibbon, GM;Kafka, HP;Burton, JR
通讯作者:
Burton, JR
影响因子:
11.2
作者:
Kanda, S;Miyata, Y;Kanetake, T
通讯作者:
Kanetake, T
DOI:
10.1006/bbrc.1993.1616
发表时间:
1993-05-28
影响因子:
3.1
作者:
FURUYA, M;AISAKA, K;MATSUO, H
通讯作者:
MATSUO, H
影响因子:
8.7
作者:
Doi, K;Ikeda, T;Nakao, K
通讯作者:
Nakao, K